Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.49 |
| ▸ | PPARA | Q07869 | 13/20 | 0.49 |
| ▸ | PPARD | Q03181 | 12/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507189 | 0.92 | PPARG (0.51) | PPARGPPARAPPARDSLC6A4KCNH2 | |
| SCHEMBL4522609 | 0.91 | PPARG (0.59) | PPARGPPARAPPARDSLC6A4KCNH2 | |
| SCHEMBL4518446 | 0.91 | PPARG (0.58) | PPARGPPARAPPARDSLC6A4KCNH2 | |
| SCHEMBL4502542 | 0.83 | PPARG (0.63) | PPARGPPARAPPARDSLC6A4KCNH2 | |
| SCHEMBL5988726 | 0.82 | PPARG (0.70) | PPARGPPARAPPARD | |
| SCHEMBL5988723 | 0.82 | PPARG (0.70) | PPARGPPARAPPARD | |
| SCHEMBL4516713 | 0.82 | PPARG (0.61) | PPARGPPARAPPARDL3MBTL1 | |
| SCHEMBL13678680 | 0.82 | PPARG (0.61) | PPARGPPARAPPARDL3MBTL1 | |
| SCHEMBL4507768 | 0.81 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL5699027 | 0.81 | PPARG (0.55) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1675814-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037763-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.